Search results: (10000)
News What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?
Fresh findings from the BE ACTIVE study were published this year in the journal Rheumatology, which evaluated the effects of long-term treatment of individuals with psoriatic arthritis (PsA) with bimekizumab in terms of patient-reported outcomes (PROs).
News Facilitated Immunoglobulin Substitution Therapy in Paediatric Patients with Immunodeficiency – Real-World Data
Patients with humoral immunodeficiency are indicated for immunoglobulin substitution therapy. The study presented below summarizes real-world data concerning the latest substitution method (i.e., facilitated subcutaneous administration) in paediatric patients.
News Central European Expert Consensus on the Treatment of ITP in Adult Patients
In a recently published consensus, experts from Central Europe evaluate the current treatment options for immune thrombocytopenia (ITP) in adult patients and issue 7 recommendations for the administration of thrombopoietin receptor agonists (TPO-RA) in the 2nd line treatment of ITP, based on an analysis of 31 randomized controlled trials.
News What can we base the decision on for the choice of initial treatment modality for CLL?
We now have a range of highly effective treatment options for patients with chronic lymphocytic leukemia (CLL). New drugs have significantly contributed to improved overall survival (OS). However, there are still questions about the most appropriate treatment regimen or criteria for choosing the initial therapeutic modality. Some of these questions are posed—and answers sought—by Professor John F. Seymour from the University of Melbourne in his recent communication.
News Omalizumab and Treatment of Severe Refractory Asthma in Pregnant Women
Omalizumab is commonly recommended for the treatment of severe refractory asthma. A special group of patients are pregnant women with asthma, for whom the risks of inadequately treated asthma must be weighed against the risks of biological treatment for the fetus. EXPECT is a pregnancy registry that has served since 2006 as a prospective observational study; its aim is to collect data on women treated with omalizumab during pregnancy and compare it with data from asthmatic women who did not receive omalizumab.
News COPD is Treated Differently Across Europe – What Could Be the Reasons for This Variability?
As part of this year's Hradec Pneumological Days (HPD 2022), the head of the Pulmonary Clinic at Charles University Faculty of Medicine and University Hospital Hradec Králové, Assoc. Prof. Vladimír Koblížek, M.D., Ph.D., reflected on the different rates of prescription of mucoactive drugs to COPD patients in various European countries. According to him, it is clear that in real practice, this treatment works. So what is the reason for its varying prescription across the old continent?
News Analysis of the Benefits and Risks of Superabsorbent Dressings in the Treatment of Moderate to Highly Exuding Leg Ulcers
A study on the benefits and risks of superabsorbent dressings compared to standard dressings in the treatment of moderate to highly exuding leg ulcers was published last year in The International Journal of Lower Extremity Wounds.
News Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
The aging population of individuals with hemophilia brings new experiences and challenges, leading to the search for the safest and most effective treatments and prevention strategies for diseases typical of older age, particularly cardiovascular and cerebrovascular diseases. It is important to recognize that these complications pose a real risk for individuals with hemophilia, a risk that has thus far been somewhat underestimated.
News Is it possible to predict survival time based on laboratory or radiological findings in patients with IPF?
High-resolution computed tomography (HRCT) imaging of the lungs is a fundamental examination in diagnosing idiopathic pulmonary fibrosis (IPF). According to experts from the Mayo Clinic, it can also serve as a tool for more accurate prediction of survival time in IPF patients.
News Venetostart – The First Comprehensive Mobile Application with Practical Information for Venetoclax Treatment
Abbvie has developed the comprehensive mobile application Venetostart with practical information needed in clinical practice for administering venetoclax (Venclyxto), which is indicated for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
News ID 360 – Immunodeficiency in Interdisciplinary Collaboration 2022
For the second time, a two-day meeting titled "ID 360 – Immunodeficiency in Interdisciplinary Collaboration" took place, this time on March 25–26, 2022, in Prague. Several current topics were discussed during this professional event, which brings together experts who care for patients with primary or secondary immunodeficiencies. The meeting was professionally guaranteed by Prof. MUDr. Anna Šedivá, DSc., from the Institute of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital Motol in Prague.
News Case Study with Voting: Intensification of Type 2 Diabetes Therapy in a Chronically Treated Patient. How to Proceed According to Current Recommendations?
We have prepared an interactive case study for you with a 70-year-old patient with decompensated Type 2 Diabetes. The patient was diagnosed with DM eight years ago. What treatment approach would you choose? And why? And how should you correctly proceed according to the current recommendations of SVL? Watch a short video with us.
News Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
The immunosuppressive ozanimod was approved for the treatment of ulcerative colitis (UC) based on the results of the phase III clinical trial True North. An open-label study followed this and previous clinical evaluations, focusing particularly on the efficacy of long-term use of ozanimod. What insights did the subsequent monitoring bring?
News Reverse Remodeling of LV in Patients with Diabetes/Prediabetes and Heart Failure with Reduced Ejection Fraction Treated with Empagliflozin
Authors of the British study SUGAR-DM-HF published in February 2021 examined whether empagliflozin reduces left ventricle (LV) volume in patients with type 2 diabetes mellitus (DM), prediabetes, and heart failure with reduced ejection fraction (EF). This favorable reverse remodeling of the LV could be a mechanism through which empagliflozin achieves reduced hospitalization rates for heart failure and overall mortality in these patients.
News Impact of Initial RAAS Inhibitor on Hospitalization Risk in HFrEF Patients
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is considered a key step in the treatment of heart failure with reduced ejection fraction (HFrEF). The preferred medication currently is the angiotensin II receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan, which has shown to improve the prognosis of patients with HFrEF. A recently published study compared the initiation of ARNI or angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) in patients with HFrEF who were not previously treated with a RAAS inhibitor in real-world practice.
News ERS 2023: Erdostein and its Metabolite Met-1 Modulate Innate Immunity and Oxidative Stress in SARS-CoV-2 Infection
As part of the September congress of the European Respiratory Society (ERS 2023), the issue of COVID-19 was also addressed. Among the late-breaking messages was an e-poster by experts from the University of Milan, who in their study examined the potential of erdosteine and its active metabolite Met-1 in treating this disease, based on research into its application to cells infected with SARS-CoV-2.
News ITP with Severe Hemorrhagic Manifestations Associated with COVID-19 – Case Study
There can be numerous causes of newly acquired immune thrombocytopenia (ITP), often being idiopathic. Severe COVID-19 can be associated with ITP manifestations where the standard first-line treatment may not be effective. In life-threatening bleeding situations, adding romiplostim has proven effective, as illustrated by the following case study from authors in Montreal, Canada.
News Focused on the Effect of Teriflunomide on Lymphocyte Subpopulations
Teriflunomide is a common choice for long-term therapy of the relapsing-remitting form of multiple sclerosis. The use of this immunomodulatory agent results in a decrease in lymphocyte numbers. Its effect on different lymphocyte subpopulations, however, has not been fully elucidated. Italian authors of a study published in the journal Neurology: Neuroimmunology and Neuroinflammation attempted to refine this knowledge.
News Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism
The relationship between the level of antithyroid antibodies and the required dose of levothyroxine in substitution for autoimmune hypothyroidism is a poorly explored question. Therefore, a retrospective study of more than 300 patients was conducted, and we bring you a brief summary.
News Does the Risk of Recurrence of Differentiated Thyroid Carcinoma Differ by Gender?
Differentiated thyroid carcinomas (DTC) are typically diagnosed at more advanced stages in men than in women, and mortality from this disease is higher among men than women. However, it was not entirely clear whether the risk of DTC recurrence is influenced by the patient's gender independently of the disease stage at the time of diagnosis. The aim of the Canadian authors' study was to assess whether male gender is an independent risk factor for DTC recurrence.
News Turoctocog Alfa Pegol in Surgical Procedures – Experiences from Pathfinder 3 and 5 Studies
The Haemophilia journal published data in May 2020 from 2 studies that summarize experiences with turoctocog alfa pegol during surgical procedures in adults, adolescents, and children with hemophilia A.
News Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy – Results of the Final Analysis of Clinical Studies
Previously published results of clinical studies have shown that in patients refractory to crizotinib therapy, the administration of brigatinib led to a high rate of therapeutic response (systemic and intracranial) and simultaneously improved median progression-free survival. Additional results presented at this year's ASCO congress included the final outcomes of studies focusing on the administration of brigatinib specifically in patients refractory to crizotinib therapy.
News Assessment of the Effectiveness of Superabsorbent Dressings from the Perspective of Doctors and Patients
The Journal of Wound Care published the results of an observational study on the benefits of Resposorb Super superabsorbent dressings in the treatment of acute and chronic wounds with higher levels of exudate.